Yep IMO a bit to look forward to over the next 5 to 6 months (sentiment changed from none to buy):
Pharmacokinetic study expected to report further safety and tolerability data
from higher dose levels over longer duration in the coming weeks
Lead compound NYX-PCSK9i selected and demonstrated efficacy equivalency to
the two FDA approved monoclonal PCSK9 antibody drugs
Interim results from an ongoing in vivo efficacy study of NYX-PCSK9i by the end
of 2020 with final results expected in early 2021
Strong cash position, with A$5.2 million in cash as at 30 September 2020, providing
cash runway until the end of 2021
Nyrada founder and seasoned biotech entrepreneur, Dr Ian Dixon joins the Board as
Non-Executive Director
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.010(4.26%) |
Mkt cap ! $51.67M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 25.0¢ | 23.0¢ | $143.6K | 590.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 60000 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 159081 | 1 |
View Market Depth
| Last trade - 15.59pm 20/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |